Trivitron Healthcare, a medical device manufacturing company in Chennai, has launched a patented newborn screening (NBS) kit that can detect up to 50 inborn disorders. The kit, NeoMass AAAC, allows accurate determination of metabolic disorders the newborn might be born with or without any immediate symptoms or visible manifestations, making it the broadest available panel of biomarkers, according to the company. The blood test within 72 hours of birth checks for the possibility of life threatening disorders. The kit uses tandem mass spectrometry technology. GSK Velu, Chairman and Managing Director, said the launch of the kit makes Trivitron a complete solution provider for NBS.